Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ONCO - Onconetix Inc


IEX Last Trade
0.133
-0.001   -0.752%

Share volume: 411,134
Last Updated: Fri 30 Aug 2024 09:19:21 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.13
0.00
-0.75%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-12.95%
1 Month
-18.14%
3 Months
-42.92%
6 Months
-20.91%
1 Year
-83.03%
2 Year
-95.93%
Key data
Stock price
$0.13
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.10 - $0.78
52 WEEK CHANGE
-$0.82
MARKET CAP 
4.045 M
YIELD 
N/A
SHARES OUTSTANDING 
29.790 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,070,231
AVERAGE 30 VOLUME 
$3,917,339
Company detail
CEO:
Region: US
Website: https://www.bluewatervaccines.com/
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.

Recent news